CARotid plaqUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study

2021 ◽  
Author(s):  
Tiziana Claudia Aranzulla ◽  
Salvatore Piazza ◽  
Andrea Ricotti ◽  
Giuseppe Musumeci ◽  
Andrea Gaggiano
Keyword(s):  
Carotid Plaque ◽  
Plaque Stabilization

scholarly journals Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization

2010 ◽  
Vol 51 (1) ◽  
pp. 114-121 ◽  
Author(s):  
Nikolaos P.E. Kadoglou ◽  
Nikolaos Sailer ◽  
Anestis Moumtzouoglou ◽  
Alkistis Kapelouzou ◽  
Thomas Gerasimidis ◽  
...  
Keyword(s):  
Carotid Plaque ◽  
Lipid Lowering ◽  
Plaque Stabilization

Statin treatment is associated with reduced toll-like receptor 4 immunohistochemical expression on carotid atherosclerotic plaques: a novel effect of statins

Vascular ◽  
2011 ◽  
Vol 19 (6) ◽  
pp. 320-326 ◽  
Author(s):  
Athanasios Katsargyris ◽  
Chris Klonaris ◽  
Sotirios Tsiodras ◽  
Elias Bastounis ◽  
Athanasios Giannopoulos ◽  
...  
Keyword(s):  
Carotid Plaque ◽  
Statin Treatment ◽  
Atherosclerotic Plaques ◽  
Toll Like Receptor ◽  
Tlr4 Expression ◽  
Immunohistochemical Expression ◽  
Toll Like Receptor 4 ◽  
Over Expression ◽  
Plaque Stabilization ◽  
Plaque Destabilization

Toll-like receptor 4 (TLR4) has been recently implicated in inflammatory pathways involved in carotid plaque destabilization. Given that statins have plaque stabilization and inflammation reduction effects, we investigated whether TLR4 expression on carotid atherosclerotic plaques correlates with statin intake. Carotid atherosclerotic plaques were obtained on 140 patients (preoperative statin intake, n = 70). TLR4 immunohistochemical expression was investigated in endothelial cells (ECs), macrophages (MACs) and smooth muscle cells (SMCs) of carotid atheroma. TLR4 positivity, over-expression and intensity of immunostaining were compared in statin versus no-statin users. The results of this study showed that statin users had a significantly lower expression of TLR4 in ECs ( P = 0.02, 0.001, 0.006 for TLR4 positivity, increased intensity and over-expression, respectively). Similarly, TLR4 positivity was less pronounced in carotid plaque MACs of statin users ( P = 0.03). No carotid specimen with increased EC TLR4 intensity or over-expression was observed among statin users. The prevalence of any cerebrovascular accident was 61.4% in the ‘no statin’ versus 18.6% in the ‘statin’ group (odds ratio for statin use: 0.14, 95% CI: 0.07–0.31, P < 0.001). In conclusion, statin treatment is associated with attenuated TLR4 expression on human carotid atherosclerotic plaques and a reduced risk of carotid-related cerebrovascular events. TLR4 may potentially mediate statins' plaque stabilization effects. Further investigation is necessary.

scholarly journals SS11. Aggressive Lipid-Lowering is More Effective Than Moderate Lipid-Lowering Treatment in Carotid Plaque Stabilization

2009 ◽  
Vol 49 (5) ◽  
pp. S4-S5 ◽  
Author(s):  
Nikolaos P.E. Kadoglou ◽  
Nikolaos Sailer ◽  
Anestis Moumtzouoglou ◽  
Alkistis Kapelouzou ◽  
Grigorios Fotiadis ◽  
...  
Keyword(s):  
Carotid Plaque ◽  
Lipid Lowering ◽  
Plaque Stabilization

scholarly journals Carotid Plaque Stabilization and Progression After Stroke or TIA

2009 ◽  
Vol 29 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Renu Virmani ◽  
Aloke V. Finn ◽  
Frank D. Kolodgie
Keyword(s):  
Carotid Plaque ◽  
Plaque Stabilization

P1.32 THE HIGH DOSE ATORVASTATIN TREATMENT ALLOWS TO ACHIEVE ECHOLUCENT SYMPTOMATIC CAROTID PLAQUE STABILIZATION

2013 ◽  
Vol 7 (3-4) ◽  
pp. 118
Author(s):  
O.V. Tereshina ◽  
E.A. Surkova ◽  
A.N. Vachev
Keyword(s):  
Carotid Plaque ◽  
High Dose ◽  
Atorvastatin Treatment ◽  
Symptomatic Carotid ◽  
Plaque Stabilization

scholarly journals CRT-309 Body Mass Index is a Positive Determinant of Carotid Plaque Stabilization During Statin Therapy Assessed by MRI

2014 ◽  
Vol 7 (2) ◽  
pp. S42
Author(s):  
Ryo Naito ◽  
Katsumi Miyauchi ◽  
Hiroyuki Daida
Keyword(s):  
Body Mass Index ◽  
Statin Therapy ◽  
Body Mass ◽  
Carotid Plaque ◽  
Plaque Stabilization ◽  
Positive Determinant

Carotid Plaque Burden Is Shown To Predict Cardiovascular Death

2005 ◽  
Vol 38 (18) ◽  
pp. 58
Author(s):  
SHERRY BOSCHERT
Keyword(s):  
Carotid Plaque ◽  
Cardiovascular Death ◽  
Plaque Burden

Association of plaque echostructure and cardiovascular risk factors with symptomatic carotid artery disease

VASA ◽  
2009 ◽  
Vol 38 (4) ◽  
pp. 357-364 ◽  
Author(s):  
Giannoukas ◽  
Sfyroeras ◽  
Griffin ◽  
Saleptsis ◽  
Antoniou ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Carotid Artery ◽  
Cardiovascular Risk Factors ◽  
Carotid Plaque ◽  
Young Patients ◽  
Symptomatic Disease ◽  
Age Related ◽  
Ica Stenosis

Background: Severity of stenosis remains the main factor for assessing risk of stroke in patients with internal carotid artery (ICA) disease. This study was conducted to investigate the association of plaque echostructure and other established and emerging cardiovascular risk factors with symptomatic ICA disease. Design: Cross-sectional study of consecutive patients with significant (> 50 %) ICA stenosis. Patients and methods: Carotid plaque echostructure, smoking, hypertension, diabetes mellitus, serum lipoprotein (a), homocysteine, vitamin B12, folate, cholesterol to high-density lipoprotein ratio, triglycerides, C-reactive protein, and the Framingham risk score were assessed in 124 consecutive patients (70 asymptomatic; 54 symptomatic) with significant (> 50 %) ICA stenosis. Results: The asymptomatic and symptomatic groups did not differ in terms of gender distribution (p = 0.76) and severity of stenosis (p = 0.62). Echolucent plaques (type 1 and 2) were more predominant in patients with symptomatic disease (p = 0.004, OR = 2.13, 95 % CI = 1.26-3.6). Patients with plaques type 1 were relatively younger than those with type 4 (p = 0.02). None of the other factors assessed had any significant association with symptomatic disease and any type of carotid plaque. Conclusions: Besides the severity of carotid stenosis, the presence of an echolucent plaque appears as an important factor associated with symptomatic ICA disease. Also, young patients are more likely to have an echolucent plaque suggesting an age-related association with plaque maturation.

Statins and Vulnerable Plaque

2018 ◽  
Vol 23 (46) ◽  
pp. 7069-7085 ◽  
Author(s):  
Maria Drakopoulou ◽  
Konstantinos Toutouzas ◽  
Archontoula Michelongona ◽  
Dimitrios Tousoulis
Keyword(s):  
Statin Therapy ◽  
Vulnerable Plaque ◽  
Vascular Wall ◽  
Statin Treatment ◽  
Duration Of Treatment ◽  
Fibrous Cap ◽  
Plaque Development ◽  
Plaque Stabilization ◽  
Inflammatory Activation ◽  
The One

Background: Atherosclerosis is a systemic, progressive lipid-driven inflammatory disease of the arterial vascular wall leading progressively to plaque development. The vulnerable plaque, the one considered to be the leading cause of cardiovascular events seems to exhibit a large and soft lipid-rich necrotic core covered by a thin and inflamed fibrous cap. Statin treatment is considered as one of the most effective methods for vulnerable plaque stabilization, currently being the principal drug in primary and secondary prevention of cardiovascular disease. </P><P> Objective: We sought to evaluate the beneficial effect of statins on biological processes involved in the evolution of vulnerable plaques </P><P> Method: We performed a systematic review of the literature searching MEDLINE via Pubmed for all experimental and human studies implementing statins in vulnerable plaque. </P><P> Results: Statins seem to have a beneficial role in plaque stabilization and patient outcome. It seems that this effect is mediated by improving endothelial function, decreasing oxidative stress and inflammation, reducing inflammatory activation and inhibiting thrombogenic response. Although these data are quite promising, it remains to be determined the extent of a potent benefit of the pleiotropic effects of statin therapy in clinical setting. </P><P> Conclusion: Prospective randomized trials should be conducted in order to further elucidate differences among type and dose of statin therapy, duration of treatment and association with LDL levels and clinical outcome.

Sign in / Sign up

Export Citation Format

Share Document